Piper Jaffray Companies reiterated their buy rating on shares of Illumina (NASDAQ:ILMN) in a report released on Tuesday. The firm currently has a $269.00 price target on the life sciences company’s stock.
Several other equities analysts also recently issued reports on ILMN. Evercore ISI began coverage on shares of Illumina in a research note on Wednesday, January 3rd. They issued an outperform rating and a $250.00 price objective for the company. Goldman Sachs Group reiterated a neutral rating and set a $200.00 target price on shares of Illumina in a research note on Tuesday, September 26th. BTIG Research assumed coverage on shares of Illumina in a research note on Friday, January 5th. They set a neutral rating for the company. William Blair downgraded shares of Illumina from an outperform rating to a market perform rating in a research note on Friday, January 5th. Finally, BidaskClub upgraded shares of Illumina from a hold rating to a buy rating in a research note on Friday, January 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $214.38.
Illumina (NASDAQ:ILMN) opened at $244.72 on Tuesday. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina has a 12 month low of $156.50 and a 12 month high of $245.96. The stock has a market cap of $35,045.84, a price-to-earnings ratio of 45.83, a price-to-earnings-growth ratio of 3.23 and a beta of 0.79.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company had revenue of $714.00 million during the quarter, compared to the consensus estimate of $692.77 million. During the same quarter in the prior year, the firm posted $0.97 earnings per share. Illumina’s revenue for the quarter was up 17.6% on a year-over-year basis. equities research analysts forecast that Illumina will post 3.76 EPS for the current fiscal year.
In related news, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $210.43, for a total transaction of $4,208,600.00. Following the completion of the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at $113,458,805.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of the stock in a transaction dated Saturday, December 29th. The stock was sold at an average price of $217.38, for a total transaction of $271,725.00. Following the transaction, the director now directly owns 8,838 shares of the company’s stock, valued at $1,921,204.44. The disclosure for this sale can be found here. Insiders have sold 137,671 shares of company stock valued at $29,485,768 over the last three months. 0.89% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of ILMN. Winslow Capital Management LLC purchased a new position in Illumina in the second quarter valued at about $211,584,000. Fred Alger Management Inc. increased its holdings in Illumina by 611.9% in the second quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after buying an additional 548,030 shares in the last quarter. TIAA CREF Investment Management LLC increased its holdings in Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares in the last quarter. Capital World Investors increased its holdings in Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in Illumina by 1,556.2% in the second quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock valued at $57,263,000 after buying an additional 310,084 shares in the last quarter. 91.60% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Illumina (ILMN) Stock Rating Reaffirmed by Piper Jaffray Companies” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/illumina-ilmn-stock-rating-reaffirmed-by-piper-jaffray-companies.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.